This Is MS Multiple Sclerosis Knowledge & Support Community

Dimethyl fumarate achieves no evidence of disease activity in MS patients

Data analysis of two previous trials has shown that a higher number of patients with relapsing remitting multiple sclerosis (RRMS) achieved no evidence of disease activity (NEDA), over a two year period, with delayed-release dimethyl fumarate (DMF) compared to a placebo...Read more - http://www.ms-uk.org/dimethyl-fumarate- ... nts-210417

The title of this post is inaccurate and deceiving.



The purpose of the study was "to evaluate the effect of DMF on achieving no evidence of disease activity (NEDA) "

And actually, the conclusion of the study was:

"A significantly higher percentage of patients treated with DMF achieved NEDA status over 2 years compared with placebo."

Here is a link to the study:

https://www.ncbi.nlm.nih.gov/pubmed/28328179


Per MSUK's own release:

Data analysis of two previous trials has shown that a higher number of patients with relapsing remitting multiple sclerosis (RRMS) achieved no evidence of disease activity (NEDA), over a two year period, with delayed-release dimethyl fumarate (DMF) compared to a placebo.




In any case, the results seem somewhat favorable anyway. Copaxone was also used in the study and had very similar results.